Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of DTPa-HBV-IPV/Hib-MenC-TT vaccination in healthy infants
2009-016635-36Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus, Haemophilus influenzae type b, meningococcal C conjugate vaccine in diphtheria, Tetanus, pertussis and 6 more (2 arms), sponsored by GSK. Primary endpoints: Immunogenicity to Hib and MenC after dose 2, Immunogenicity to D, T, HBs, IPV1-3 and pertussis after dose 2 and 2 more. Started Jan 2010; status: completed.
02
Drugs
diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus, Haemophilus influenzae type b, meningococcal C conjugate vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on 2009-016635-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016635-36.